Analyst Price Targets — SRZN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 7, 2026 10:12 am | — | H.C. Wainwright | $44.00 | $34.13 | TheFly | Surrozen price target raised to $44 from $36 at H.C. Wainwright |
| February 19, 2026 11:13 am | — | Cantor Fitzgerald | $40.00 | $25.09 | TheFly | Surrozen initiated with an Overweight at Cantor Fitzgerald |
| January 30, 2025 11:04 am | Matthew Caufield | H.C. Wainwright | $32.00 | $11.25 | TheFly | Surrozen initiated with a Buy at H.C. Wainwright |
| January 3, 2025 11:15 am | Yatin Suneja | Guggenheim | $45.00 | $17.45 | TheFly | Surrozen upgraded to Buy from Neutral at Guggenheim |
Latest News for SRZN
Surrozen to Present at Upcoming Healthcare Investor Conference: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026
SOUTH SAN FRANCISCO, Calif. , July 15, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.
On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Well-capitalized with $106.9 million in cash and cash equivalents as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to…
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on April 24, 2026, Surrozen granted a non-statutory stock option for an aggregate of…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SRZN.
U.S. House Trading
No House trades found for SRZN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.